Log in
CLL Support Association
11,366 members17,484 posts

Monoclonal B-cell lymphocytosis or MBL and a new clinical trial for those resistant to ibrutinib and more


This week I'm posting an interview that took place at ASH 2016 with Dr. Neil Kay from the Mayo Clinic in Rochester, MN where we discussed monoclonal B-cell lymphocytosis or MBL, which is felt to be a precursor to CLL. You can view my summary, and watch the interview here: cllsociety.org/2017/06/mbl-...

I have posted interviews and articles about research that is being conducted to study treatment options for patients with relapsed or refractory CLL. On occasion I want to make everyone aware of a clinical trial that is starting that might be of interest. I have posted some information about a trial for patients with relapsed refractory CLL who have received 2 or more prior treatments, including treatment with a BTK inhibitor such as ibrutinib or acalabrutinib. You can read more about it here: cllsociety.org/2017/06/new-... It involves the new Sunesis drug that binds differently to BTK and so in theory should work for those who become resistance to the other BTK blockers due to a mutation in the C481 binding site, the leading known cause of resistance.

Stay strong.

We are all in this together.




You may also like...